• 1
    Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of thirteen participating institutions evaluating 3,885 patients. J. Urol. 1989; 141: 2437.
  • 2
    McConnell JD. Epidemiology, etiology, pathophysiology, and diagnosis of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ (eds). Campbell's Urology Vol. 2, 7th edn. WB Saunders, Philadelphia 1998, 142952.
  • 3
    Gordon NS, Hadlow G, Knight E, Mohan P. Transurethral resection of the prostate: Still the gold standard. Aust. NZ J. Surg. 1997; 67: 3547.
  • 4
    Chapple CR. Introduction and concluding remarks on BPH disease management. Eur. Urol. 1999; 36: 16.
  • 5
    Bruskewitz R. Management of symptomatic BPH in the US. Who is treated and how? Eur. Urol. 1999; 36: 713.
  • 6
    Roehrborn CG. The newly established guidelines for the diagnosis and management of benign prostatic hyperplasia. Curr. Opion. Urol. 1995; 5: 305.
  • 7
    Bergers RR, Pienthka L. Management of the BPH Syndrome in Germany: Who is treated and how? Eur. Urol. 1999; 36: 217.
  • 8
    Michel MC, Goepel M. Lower urinary tract symptoms suggestive of benign prostatic obstruction − what's the long-term effectiveness of medical therapies? Eur. Urol. 2001; 39: 205.
  • 9
    Zimmern P. Medical treatment modalities for lower urinary tract symptoms: what are the relevant differences in randomised controlled trials? Eur. Urol. 2000; 38: 1824.
  • 10
    Speakman MJ. Who should be treated and how? Evidence-based medicine in symptomatic BPH. Eur. Urol. 1999; 36: 4051.
  • 11
    Fowler FJ, Wennberg JE, Timothy RP, Barry MJ, Mulley AG, Hanley D. Symptom status and quality of life following prostatectomy. JAMA 1988; 259: 301822.
  • 12
    Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 11926.
  • 13
    Debruyne FM. Alpha blockers: are all created equal? Urology 2000; 56: 202.
  • 14
    McNicholas TA. Management of symptomatic BPH in the UK. Who is treated and how? Eur. Urol. 1999; 36: 339.
  • 15
    Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur. Urol. 2000; 38: 219.
  • 16
    Fawzy A, Hendry A, Cook E, Gonzalez F. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment concurrent benign prostatic hyperplasia and hypertension. Int. J. Urol. 1999; 6: 34654.
  • 17
    Barry MJ, Fowler FJ, Bin L, Pitts JC, Harris , CJ, Mulley AG Jr. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J. Urol. 1997; 157: 105.
  • 18
    Stoevelaar HJ, Van de Beek C, Casparie AF, McDonnell J, Nijs HG. Treatment choice for benign prostatic hyperplasia: a matter of urologist preference? J. Urol. 1999; 161: 1338.
  • 19
    Borth CS, Beiko DT, Nickel JC. Impact of medical therapy on transurethral resection of the prostate. A decade of change. Urology 2001; 57: 10826.
  • 20
    Roehrborn CG, Bartsch G, Kirby R. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001; 58: 64250.